# Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

Study · id `cardio:ct-nct04892199` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04892199](<https://clinicaltrials.gov/study/NCT04892199>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04892199

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 104 participants.

## Technical summary

Registry record NCT04892199. Randomized; triple masking; primary purpose treatment. Start 2021-09-01 (actual); primary completion 2026-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 104 participants (planned count; ClinicalTrials.gov record NCT04892199, source copy `cardio:ctgov-nct04892199-2024-09-25`, retrieved 2026-10-26)
- Started: 2021-09-01 (actual) (ClinicalTrials.gov record NCT04892199, source copy `cardio:ctgov-nct04892199-2024-09-25`, retrieved 2026-10-26)
- Primary completion: 2026-03-01 (anticipated) (ClinicalTrials.gov record NCT04892199, source copy `cardio:ctgov-nct04892199-2024-09-25`, retrieved 2026-10-26)
- Completion: 2026-08-01 (anticipated) (ClinicalTrials.gov record NCT04892199, source copy `cardio:ctgov-nct04892199-2024-09-25`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT04892199, source copy `cardio:ctgov-nct04892199-2024-09-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04892199-2024-09-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
- Condition: Metabolic Disturbance
- Condition: Schizophrenia
- Condition: Type 2 Diabetes
- Condition: Clozapine
- Condition: GLP-1
- Condition: Olanzapine
- Intervention (Drug): Semaglutide, 1.34 mg/mL
- Intervention (Drug): Semaglutide-placebo
- Lead sponsor: Anders Fink-Jensen, MD, DMSci
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)

## Provenance

Content hash: 49963590f4085425bc6823592793353581e559c466898ec490201500dd68c758
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
